Technologies

Medical Sciences, Life Sciences & Biotechnology

Title:	Process for Preparation of a Biomarker Specific for O-acetylated sialic acid Useful for Diagnosing, Monitoring Treatment Outcome, and Predicting Relapse of Lymphoblastic Leukemia
Area:	Medical Sciences, Life Sciences & Biotechnology
Focus Area:	Lymphoblastic Leukemia
Patent:	IN191209
Social Benefits:	To provide a reagent, a novel biomarker specific for O-acety!ated sialic acid, by an simple process with a significant high yield. The reagent has an amplified biological potency to bind with cancer cells, therefore it has tremendous potential in terms of its detection capability of ALL patients under different phases of treatment eg. Potential for diagnosis and prognosis of ALL patients. Furthermore, the process for purification of a novel biomarker specific for O-acetylated sialic acid is not a complicated one and comprises only a few simple steps including removal of other non -O-acetylated proteins by using asialo bovine submaxillary mucin affinity column followed by capturing novel O-acetylated sialic acid specific biomarker using a bovine submaxillary mucin - Sepharose column. Thus a novel biomarker specific for O-acetylated sialic acid purified from these patients serum is of significant and maximum potency in detecting ALL patients under different phases of treatment i.e. detection of minimal residual disease in ALL, which is a challenging problem for leukemia specialist. To provide a reagent by a process" with a significant commercial application and can predict relapse. For diagnosis of ALL patients of different lineages e.g. T cell ALL, B cell ALL and mixed lineage ALL having cancer in both B and T lymphocytes by this novel biomarker specific for O-acetylated sialiclcid reflecting its general expression. It can distinguish between different stages of acute lymphoblastic leukemia which correlate well with the clinical status of the disease. It detects the extent to which the patient has responded to chemotherapy. Serum from other hematological disorder does not possess this biomarker Normal human serum contain very insignificant amount of this biomarker.
Developing Agency:	CSIR-Indian Institute of Chemical Biology (IICB), West Bengal
Technology Readiness Index:	Lab Validation
Email:	director@iicb.res.in
Website Link :	http://www.iicb.res.in
Source (more info) :	https://t.ly/l_sb

Brief Description

Description :

Preparation of a novel biomarker specific for O-acetylated sialic acid useful for the diagnosis, monitoring outcome of treatment and prediction of relapse of Acute lymphoblastic leukemia (ALL). The so generated reagent will serve as an effective measure in the battle for monitoring treatment outcome in patients suffering from acute lymphoblastic leukemia.